+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Immune Disorders Drugs Market Research Reports

Systemic Lupus Erythematosus - Epidemiology Forecast to 2032 - Product Thumbnail Image

Systemic Lupus Erythematosus - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Systemic Mastocytosis - Epidemiology Forecast to 2032 - Product Thumbnail Image

Systemic Mastocytosis - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Graves Disease - Epidemiology Forecast to 2032 - Product Thumbnail Image

Graves Disease - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Febrile Neutropenia - Epidemiology Forecast to 2032 - Product Thumbnail Image

Febrile Neutropenia - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
From
From
Autoimmune Gastritis - Epidemiology Forecast - 2032 - Product Thumbnail Image

Autoimmune Gastritis - Epidemiology Forecast - 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Immune Thrombocytopenia (ITP) - Epidemiology Forecast to 2032 - Product Thumbnail Image

Immune Thrombocytopenia (ITP) - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Adult-onset Still's Disease - Epidemiology Forecast to 2032 - Product Thumbnail Image

Adult-onset Still's Disease - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Myositis - Pipeline Insight, 2025 - Product Thumbnail Image

Myositis - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 80 Pages
  • Global
From
Chronic Spontaneous Urticaria - Pipeline Insight, 2025 - Product Thumbnail Image

Chronic Spontaneous Urticaria - Pipeline Insight, 2025

  • Clinical Trials
  • July 2025
  • 80 Pages
  • Global
From
Graves' Disease - Pipeline Insight, 2025 - Product Thumbnail Image

Graves' Disease - Pipeline Insight, 2025

  • Drug Pipelines
  • July 2025
  • 60 Pages
  • Global
From
Chronic Rhinosinusitis - Pipeline Insight, 2025 - Product Thumbnail Image

Chronic Rhinosinusitis - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 40 Pages
  • Global
From
Crohn's Disease - Pipeline Insight, 2025 - Product Thumbnail Image

Crohn's Disease - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 240 Pages
  • Global
From
Chronic Otitis Media - Pipeline Insight, 2025 - Product Thumbnail Image

Chronic Otitis Media - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 40 Pages
  • Global
From
Psoriasis - Pipeline Insight, 2025 - Product Thumbnail Image

Psoriasis - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 100 Pages
  • Global
From
Interleukin-18 (IL-18) Inhibitor - Pipeline Insight, 2025 - Product Thumbnail Image

Interleukin-18 (IL-18) Inhibitor - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Interleukin-2 (IL-2) Inhibitor - Pipeline Insight, 2025 - Product Thumbnail Image

Interleukin-2 (IL-2) Inhibitor - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
From
Gout - Pipeline Insight, 2025 - Product Thumbnail Image

Gout - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
Loading Indicator

The Immune Disorders Drugs market is a sector of the pharmaceutical industry that focuses on the development and production of drugs to treat immune system disorders. These drugs are used to treat a variety of conditions, including allergies, asthma, autoimmune diseases, and cancer. Immune Disorders Drugs are designed to target specific parts of the immune system, such as cytokines, antibodies, and T-cells, to reduce inflammation and improve the body's ability to fight off infection. The Immune Disorders Drugs market is highly competitive, with many large pharmaceutical companies competing for market share. Some of the major players in the market include AbbVie, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Merck, Novartis, Pfizer, and Roche. These companies are constantly researching and developing new drugs to treat immune system disorders, as well as improving existing treatments. Show Less Read more